Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9ULG1
UPID:
INO80_HUMAN
Alternative names:
DNA helicase-related INO80 complex homolog 1; DNA helicase-related protein INO80; INO80 complex subunit A
Alternative UPACC:
Q9ULG1; A6H8X4; Q9NTG6
Background:
Chromatin-remodeling ATPase INO80 plays a pivotal role in transcriptional regulation, DNA replication, and repair by shifting nucleosomes and binding DNA. It's part of the INO80 complex, essential for transcriptional coactivation, UV-damage repair, and microtubule assembly during mitosis, influencing chromosome segregation.
Therapeutic significance:
Understanding the role of Chromatin-remodeling ATPase INO80 could open doors to potential therapeutic strategies.